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EfficiencyIntroduction: Collecting trial data in a medical environment is at present mostly performed manually and
therefore time-consuming, prone to errors and often incomplete with the complex data considered. Fas-
ter and more accurate methods are needed to improve the data quality and to shorten data collection
times where information is often scattered over multiple data sources. The purpose of this study is to
investigate the possible benefit of modern data warehouse technology in the radiation oncology field.
Material and methods: In this study, a Computer Aided Theragnostics (CAT) data warehouse combined
with automated tools for feature extraction was benchmarked against the regular manual data-collection
processes. Two sets of clinical parameters were compiled for non-small cell lung cancer (NSCLC) and rec-
tal cancer, using 27 patients per disease. Data collection times and inconsistencies were compared
between the manual and the automated extraction method.
Results: The average time per case to collect the NSCLC data manually was 10.4 ± 2.1 min and
4.3 ± 1.1 min when using the automated method (p < 0.001). For rectal cancer, these times were
13.5 ± 4.1 and 6.8 ± 2.4 min, respectively (p < 0.001). In 3.2% of the data collected for NSCLC and 5.3%
for rectal cancer, there was a discrepancy between the manual and automated method.
Conclusions: Aggregating multiple data sources in a data warehouse combined with tools for extraction of
relevant parameters is beneficial for data collection times and offers the ability to improve data quality.
The initial investments in digitizing the data are expected to be compensated due to the flexibility of the
data analysis. Furthermore, successive investigations can easily select trial candidates and extract new
parameters from the existing databases.
 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 174–179Collecting data in a medical environment for research purposes
is time consuming, prone to errors and often incomplete when
complex data, such as dosimetric data are concerned [1,2]. Faster
and more accurate access to medical information is required to im-
prove the data quality, shorten data-collection times and reduce
cost. Furthermore, conducting trials in multiple centres and data-
sharing are required in numerous research projects to validate trial
results, enable the collection of larger datasets of trial patients with
a rare disease or to conduct in silico trials [1,3–6]. Although the
medical community has undertaken numerous efforts to digitize
its patient and treatment documentation, data are still predomi-
nantly collected from paper charts. And when data are collected
digitally, they are in most cases unstructured and distributed over
multiple data sources.With the growing number of diagnostic and therapeutic modal-
ities comes an increasing demand for clinical trials to provide the
evidence base for these new options and to provide guidance to
healthcare providers. However, with only around 3% of the adult
cancer patients included in clinical trials this is a very hard task
[7–9]. The use of healthcare information systems based on multi-
parametric electronic medical record databases (EMR) and data
mining tools will greatly enhance clinical research in oncology
and more specifically in radiation oncology and facilitate trials
with easy patient selection and improved data quality.
Because data are often scattered and unstructured throughout a
medical care organization, data warehouse technology is suitable
to combine data sources, validate consistency and share data with
other researchers [10–12]. It can integrate various information sys-
tems in the healthcare enterprise and offers the ability to have spe-
cific data structures/views for different investigations, which may
deviate from the structure of the operational systems.
Benefits of data warehousing have been described on multiple
levels, such as time-saving for users, improved quantity and qual-
ity of information, informed decision-making, improvement of
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of strategic business objectives [13]. Data warehousing is increas-
ingly used in healthcare to provide the tools for decision making
and individualizing disease management [14,15]. Furthermore, it
is essential to facilitate the (translational) research that is needed
to develop new treatment programmes and support clinical trials
(i.e. with quality assurance programmes) [16–20].
To this end, we developed a research portal with an industrial
partner to integrate the essential medical data sources and offer
automated data extraction tools for research purposes. In this
study, we test the performance of this portal with data mining
tools against the manual collection process for clinical trials. Per-
formance is measured in time expenses and data quality to target
the hypothesis that these will decrease and improve, respectively,
by the use of a data warehouse.Fig. 1. Schematic overview of the CAT data warehouse/research portal. The system
synchronizes data from clinical data sources and custom services. It is also capable
of collecting data for trials and data collected for other research purposes. For data
export, several modules exist in the system and are easily accessible by web-
technology (i.e. the patient browser, query builder and an electronic case report
form XML export).Methods and materials
The Computer Aided Theragnostics (CAT) research portal
Together with Siemens Knowledge Solutions (Malvern, PA, USA)
we developed a Computer Aided Theragnostics (CAT) research por-
tal. It extracts medical data from the connected systems via a syn-
chronization manager (sync manager) and stores the data centrally
in a data warehouse. The operational, patient-centric structure is
converted into a disease-centric structure suitable for research. In
our radiotherapy department, the sync manager extracts data from
various sources: (1) the electronic medical record (EMR), which is
either a structured or unstructured database, (2) the RT picture
archiving communication system (PACS), consisting of diagnostic
imaging and treatment DICOM RT data such as the treatment plans
(RTPLAN), predicted 3D dose matrices (3D-RTDOSE), delineations
(RTSTRUCT) and digitally reconstructed radiographs used for setup
verification (RTIMAGE), and (3) the Record and Verify system
(R&V) containing the actual delivered treatment parameters.
The CAT research portal currently has four core user functional-
ities (Fig. 1). The first module is the query builder, which is a tool
for the visual creation and execution of queries as well as viewing
the query results and exporting them in XML format. An integrated
data-browser (second module) is available where individual cases
can be reviewed. Thirdly, the system offers an electronic case re-
port form (eCRF) module. This enables researchers to use the sys-
tem for clinical trials. The module is built in such a way that case
report forms can be pre-populated with data extracted from the
clinical databases acquired during the sync procedure. The fourth
module is a private data-store for researchers to upload parame-
ters of interest not collected by either eCRFs or clinical systems.
In addition to the EMR, PACS and R&V systems, our department
designed custom-made, fully automated workflows in a frame-
work called DIGITrans (http://www.mistir.info/?q=digitrans). DIG-
ITrans offers a user interface and background services for data
generation, extraction and transportation for both clinical and re-
search purposes. During daily clinical practice, 2D dose-guided
radiotherapy workflows are present [21], while for research users,
workflows are defined to extract parameters from for instance
dose–volume histograms (DVH) and store the results as DICOM-
objects in the PACS system. These workflows are DICOM-driven
and can convert, validate and transfer DICOM objects throughout
the entire department and can easily be adapted to support new
parameters or modalities. Parameters of interest are stored in a
structured database. Currently, DVH parameters such as mean lung
dose (MLD), structure volumes and different volume and dose
parameters are stored in a separate structured database. A similar
extraction is done from PET scans to derive and store standardized
uptake values (SUV).The current data management process
The current trial data management process in our institute is
largely manual and when data are acquired electronically still
the case report forms have to be filled in manually. Currently, a list
of patients and the parameters that need to be collected is supplied
to the data manager, who will then identify from which system or
document the data need to be extracted. Next, the data are col-
lected manually from each system or chart. The data are noted in
an electronic document such as Microsoft Excel, Access or in an
electronic case report form (eCRF). Data are collected using the
Good Clinical Practice (GCP) guidelines as a reference [22,23].
Collection of some of the parameters mentioned requires do-
main and application specialists. For these parameters, the data
managers do not collect data (e.g. DVH or SUV parameters, which
require recalculation), but the collection is done separately by radi-
ation technologists.Experimental setup
Two hypothetical trials with representative sets of parameters
were defined for non-small cell lung cancer (NSCLC) and rectal can-
cer (Table 1). Next, a comparison was made between the manual
data collection process and the automatic data warehouse based
method. The datasets were heterogeneous so that data had to be
collected from the paper charts (manually) or EMR (automatically),
the R&V system and XiO/TrueD (manually) or the PACS. For the
measurements, the parameter sets were split into two groups;
(1) the ‘‘lookup’’ group (chart/EMR and R&V) and (2) the ‘‘recalcu-
lation’’ group (XiO/TrueD and PACS).
The manual recalculation of DVH parameters was conducted
with the treatment planning system (TPS) XiO (CMS Software, Ele-
Table 1
Parameters collected for the NSCLC and rectal cancer groups. The last columns show which data were looked up where and from which source the data were recalculated.



































V5 Lungsa XiO PACS
V20 Lungs XiO PACS
V40 Bladder XiO PACS
MLD
pb XiO PACS
SUV Max Tumour TrueD PACS
SUV Mean Tumour TrueD PACS
a V5 and V20 data for the lungs were calculated with both lungs minus the PTV.
b MLD data for the lungs were calculated with both lungs minus the GTV.
176 Data mining for radiotherapy trialskta, XiO 4.34.02, St. Louis, MO), using the plans available on the TPS
system. For the manual recalculation of SUV values we used the
commercially available TrueD software (TrueD VC50, Siemens
Medical, Erlangen, Germany). The PET images were re-imported
and volumes of interest (VOIs) were created again to retrieve the
SUV data.
For the automatic recalculated parameters, a query was defined
once using the CAT research portal and the result was exported in
XML format. From this query result, the original CT/PET images,
structures and dose were sent from the PACS to the DIGITrans
workflows to automatically extract the DVH and SUV data.
Furthermore, data quality was evaluated for all experiments by
scoring discrepancies between both the CAT and current manual
process. To decide which method was correct, each deviation was
looked up again in its reference system or validated by another
observer.
The primary end-point of the experiment was data collection
time. For the sample size calculation, we hypothesized a difference
of 3 min with a standard deviation of 3 min using a paired t-test.
We wanted to achieve a power of 0.99 and an a = 0.01. Based on
these assumptions, the sample size was determined at n = 27.
The secondary end-point of data quality was evaluated by compar-
ing the output from the CAT method against the first human obser-
ver. The output of the human observer was validated by a second
human observer and inconsistencies were resolved by a third
look-up. The third look-up was not taken into account in the data
collection time measurements. After these comparisons between
observers, a GCP compliant collected data-set was acquired and
this set was also compared against the CAT method.Results
In Fig. 2, the average data collection times for NSCLC (a) and rec-
tum cancer (b) are shown for the manual versus the CAT groups.
The figure shows the distinction between the data that were
looked up (in the EMR and R&V) and recalculated (from PACS/
TPS data). On average, the total collection time for the manual
method for the individual NSCLC cases was 10.4 ± 2.1 min while
for the CAT method this was 4.3 ± 1.1 min (p < 0.001). For rectal
cancer, this was 13.5 ± 4.1 min for the manual collection and
6.8 ± 2.4 min for the CAT method (p < 0.001) (Table 2).The main difference between the manual and automatic collec-
tion times for both the NSCLC and rectum cases was caused by the
lookup parameters. The data warehouse offered one central inter-
face where all parameters were present, while the manual method
required the data managers to gather and analyse the paper charts.
For the NSCLC cases there was a difference between manual and
automated collection times of the DVH parameters. This was
caused by the fact that the V5 and V20 are not used in daily clinical
practice and their DVHs needed to be recalculated in the TPS.
For the rectal cancer cases there was a difference compared to
the NSCLC cases with respect to the collection time of recalculated
parameters. This difference was mainly caused by the extraction of
the SUVmean and SUVmax. In the manual method, VOIs needed to be
re-drawn for all cases because the used system did not support im-
port from structures or back-uped data. As can be seen in Fig. 2b
(SUV data), the standard deviation is very large (±3.0 min). This
is due to the effect that in some cases the auto-segmentation delin-
eated neighbouring organs such as the bladder and contours
needed to be edited manually. To determine the data-quality, we
compared the SUV parameters with the newly generated struc-
ture-set.
There was no difference found in the extraction of DVH param-
eters between both methods, however, the extraction took signifi-
cantly longer when compared to the NSCLC extraction. This was
because in daily clinical practice the bladder is normally not delin-
eated and therefore not available for both methods and was delin-
eated in the TPS. The time needed for the bladder delineation was
taken into account for both methods and therefore there is no dif-
ference between both methods for this extraction.
Manual data collection was performed according to GCP guide-
lines. This means that data are collected by two observers and then
validated. After validation between observers, we found that in the
NSCLC set there was a mismatch between manually collected data
and automatic in 3.2% of all different parameters collected. The
mismatch before validation for NSCLC was 10.3%. Using the GCP
collection process thus resolved 69% of the initial mismatches.
We found a particular bad concordance between observers for
the manual collection of the overall treatment time in days. This
was due to the fact that some observers erroneously recalculated
the data while others looked it up in the R&V system. This interpre-
tation difference explained most of the drop of mismatching data
after validation. The remaining differences could be explained pri-
A B
Fig. 2. Average manual versus CAT collection times (in min) for the (a) NSCLC and (b) rectum cases. The parameters that were looked up in the EMR and R&V system are
displayed in medium grey and labelled ‘‘Lookup’’. In dark grey (labelled ‘‘Recalc.’’), the parameters are shown that were recalculated. The error bars show the standard
deviations. For the rectum cases, the collection times for SUV data only show the large variability in the contribution to the recalculated parameters (in light grey and labelled
‘‘SUV’’).
Table 2
Comparison of the total data collection times (mean ± SD in min) for the manual
versus the CAT method.
Tumour type Manual (min) CAT (min) p-value
NSCLC 10.4 ± 2.1 4.3 ± 1.2 <0.001
Rectum 13.5 ± 4.1 6.9 ± 2.3 <0.001
E. Roelofs et al. / Radiotherapy and Oncology 108 (2013) 174–179 177marily by a mismatch between DVH parameters. We found that in
most cases the DVH parameters that mismatched before validation
were based on a different treatment plan than actually used for
treatment or were calculated on a wrong volume. The V5 and V20
were defined using LungLeft+LungRight–PTV(s) volumes while the
MLD had to be calculated on LungLeft+LungRight–GTV(s) volumes.
Before validation, the V5 and V20 were in some cases extracted from
the DVH from which the MLD is calculated. After the validation be-
tween observers, the remaining 3.2% mismatching parameters
indicate the true mismatch between both methods. We found that
in more than 90% of these cases the automatic method retrieved
the correct data.
For the rectal cancer set we observed similar results. We ob-
served data differences in 8.8% of all data collected. Again, we
saw a bad concordance of the overall treatment time between
the manual and automatic method. The other deviations were
mainly found in the recalculation of SUV parameters. The cause
for the deviation could be found in the implementation differ-
ences between the automated mining tool and the PET analysis
software.In the PET analysis software, a threshold is calculated by taking
into account the signal-to-background ratio calculated as Thresh-
old = 0.7813  (SUVmaxTumour/SUVmeanBackground)0.299. This thresh-
old is then used to draw the contour on the PET and all the
voxels with an SUV above the threshold are used to calculate the
SUVmean. The automated method however uses the exported con-
tour to calculate the mean SUV from all the voxels within the ex-
ported contour. Due to interpolation and inaccuracy of the
contour the SUVmean of the automated method was lower than
with the analysis software. This problem was compensated to
search the contours for the background contours, calculate the
threshold and use the threshold in the same way as the PET anal-
ysis tool. This explained 31% of the mismatches.
The remaining data inconsistencies were either human error(s),
for example in one case we found a different total delivered dose,
or were caused by erroneous DICOM objects.Discussion
Our results show that using a data-warehouse shortens data-
collection times significantly and can be of help to improve data
quality because data in the CAT data warehouse are captured from
all clinical reference systems and validated before storage in the
warehouse. Especially the use of the in-house developed mining
tools support easy extraction or recalculation of parameters of
interest (e.g. V20, V5, SUVmean and SUVmax) and eliminates manual
steps. However, as the results show with the extraction of the
SUV parameters great care must be taken when using these kinds
178 Data mining for radiotherapy trialsof tools in an automated way. It is very important to carefully val-
idate and approve them before extensive research use.
The strength of the CAT data warehouse is that it can combine,
validate and present data from distributed databases in a uniform
way. Furthermore, the system is designed to have an external
interface to share data among other institutes. Data are easily
accessible for researchers via a web-interface with several extra
options such as a patient browser and a query builder. Occasion-
ally, expert knowledge is necessary to maintain the system, be-
cause of interoperability issues due to updates of source systems.
When looking at the manual data collection process we have
found that there was a large inter-observer variability. This ex-
plains most of the data inconsistencies between the automated
and manual collection methods. Strict guidelines such as GCP
[22,23] are of great importance to ensure data quality. We found
that the collection by two observers and the monitoring and vali-
dation are vital for data quality because it resolves conflicts be-
tween observers. From previous studies [24,25] it can be
concluded that, by using intelligent free-text searching/mining
and machine learning technique approaches to retrieve the data
in a data warehouse, data can automatically be validated and true
data values can be identified. Retrieving this data manually can
introduce inconsistencies or missing data, which we have seen in
some cases in this study. This is confirmed by Prokosch and Gans-
landt [16] who mention in their second challenge that electronic
data capture for trials provides significant benefits over manual
collection. One other advantage is the possibility to include real-
time patient outcome data, for instance by directly linking to a na-
tional registry or including properly captured patient-reported
outcome [26,27].
Using the research portal for trial data collection with eCRFs
using extracted data from local databases, could possibly be a bet-
ter start of the data collection and even replace the first observer.
The electronically captured data could then immediately be vali-
dated by the monitor. By using this approach the data collection
time can be minimized. Although pre-population of data can in-
duce data capturing problems as mentioned by Kush et al. [2] this
can be solved by the requirement that the responsible eCRF repor-
ter verifies all pre-populated data. This can be embedded in the
user interface workflow. New technologies such as developed by
Rao et al. [24] can be used to validate data at the synchronization
process delivering high quality data to the user who only needs to
validate the data for the clinical trial.
The CAT research portal is an institute-specific data warehouse
that can also be used to share data in a privacy-preserving and
semantic-interoperable manner using internationally accepted
data exchange standards and ontologies such as described in an
accompanying study [28,29], addressing the growing need for
standardized data exchange between medical centres [1,3,12].
Richesson and Krischer [30] describe that there are currently over-
laps, challenges and gaps in the standards developed for research
and clinical purposes for data retrieval at a local scale and data
sharing at a global scale. They conclude that data should be shared
between research and clinics where possible but also that the clin-
ical data will have gaps and that the importance of data standards
for clinical research is underestimated. In one of a series of vision
papers by the QUANTEC group, Deasy et al. [31] suggest that
data-sharing and -pooling can raise the quantity as well as the
quality of clinical data for data mining purposes. We strongly share
this belief.
A data warehouse probably reduces cost for the research orga-
nization. As can be seen from the results from this study, data col-
lection time can be reduced significantly. Although the fact that
clinical trials usually run for several years the time spent for data
collection can be reduced by more than 50%, which should trans-
late into a cost reduction of data management. However, to setup and maintain systems like this will have financial implications.
The initial installation is the most expensive part but can be spread
over several projects in multiple years. The operational cost of a
system is dependent on the organization’s needs and is variable.
For example, for typical projects datasets of several hundreds of
patients are needed [32–35]. It was estimated in one of these stud-
ies that approximately 45 h of data management can be saved,
based on a dataset of 400 patients, which is 6–7 min. per case. This
is in concordance with our findings.
For the manual collection process, we measured the time to col-
lect the actual data when the source data were available in the sub-
systems (i.e. the treatment plan was available in the TPS). How-
ever, in retrospective studies this might not be the case and data
might have to be restored from back-ups or archives. This addi-
tional time has not been taken into account in this study because
of the fact that the retrieval of data differs heavily for various back-
up-and-restore systems. Most often PACS data reside on disks,
while the TPS data are archived on tape or slow disks. Therefore,
including restoration of data would likely increase manual recalcu-
lation times significantly.
A further benefit of data warehousing is to be expected when
considering research and trials in the field of Radiomics [36], for in-
stance. This involves the high-throughput extraction of large
amounts of image features from clinical images. These quantitative
imaging features are increasingly used in treatment planning and
for monitoring patient outcome [37,38]. Because this is a rapidly
evolving research area, new features are added frequently. There-
fore, a data warehouse with easily modified data extraction ser-
vices is likely to be far more beneficial when compared to
manual data collection.Conclusions
Information technology solutions such as the CAT data ware-
house improve clinical research for radiotherapy by reducing the
time needed to collect necessary data and by improving the quality
of the data collected.
Acknowledgements
We thank C. Overhof, R. Debougnoux, A. Claessens, J. van den
Bogaard and B. Hanbeukers for their contribution. We thank Sie-
mens for their financial and technical support received for this
study. Furthermore, we acknowledge financial support from the
CTMM framework (AIRFORCE project, n 03O-103), EU 7th frame-
work program (METOXIA, EURECA), euroCAT (IVA Interreg,
www.eurocat.info), Radiomics (NIH, USA), EU IMI program (QuIC-
ConCePT), NIH-QIN (Radiomics of NSCLC U01 CA143062) and the
Dutch Cancer Society (KWF UM 2011-5020, KWF UM 2009-4454).
References
[1] Klein A, Prokosch HU, Muller M, Ganslandt T. Experiences with an
interoperable data acquisition platform for multi-centric research networks
based on HL7 CDA. Methods Inf Med 2007;46:580–5.
[2] Kush R, Alschuler L, Ruggeri R, et al. Implementing single source: the
STARBRITE proof-of-concept study. J Am Med Inform Assoc 2007;14:662–73.
[3] Knaup P, Garde S, Merzweiler A, et al. Towards shared patient records: an
architecture for using routine data for nationwide research. Int J Med Inform
2006;75:191–200.
[4] Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges
involved in a framework for multicentric radiotherapy treatment planning
studies. Radiother Oncol 2010;97:567–71.
[5] Bosmans G, Buijsen J, Dekker A, et al. An ‘‘in silico’’ clinical trial comparing free
breathing, slow and respiration correlated computed tomography in lung
cancer patients. Radiother Oncol 2006;81:73–80.
[6] Ollers M, Bosmans G, van Baardwijk A, et al. The integration of PET-CT scans
from different hospitals into radiotherapy treatment planning. Radiother
Oncol 2008;87:142–6.
E. Roelofs et al. / Radiotherapy and Oncology 108 (2013) 174–179 179[7] Movsas B, Moughan J, Owen J, et al. Who enrolls onto clinical oncology trials? A
radiation patterns of care study analysis. Int J Radiat Oncol Biol Phys
2007;68:1145–50.
[8] Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials:
race-, sex-, and age-based disparities. JAMA 2004;291:2720–6.
[9] Grand MM, O’Brien PC. Obstacles to participation in randomised cancer clinical
trials: a systematic review of the literature. J Med Imaging Radiat Oncol
2012;56:31–9.
[10] Wisniewski MF, Kieszkowski P, Zagorski BM, Trick WE, Sommers M, Weinstein
RA. Development of a clinical data warehouse for hospital infection control. J
Am Med Inform Assoc 2003;10:454–62.
[11] Weber DC, Poortmans PMP, Hurkmans CW, Aird E, Gulyban A, Fairchild A.
Quality assurance for prospective EORTC radiation oncology trials: the
challenges of advanced technology in a multicenter international setting.
Radiother Oncol 2011;100:150–6.
[12] El Fadly A, Rance B, Lucas N, et al. Integrating clinical research with the
Healthcare Enterprise: from the RE-USE project to the EHR4CR platform. J
Biomed Inform 2011;44:S94–S102.
[13] Watson HJ, Goodhue DL, Wixom BH. The benefits of data warehousing: why
some organizations realize exceptional payoffs. Inf Manage 2002;39:491–502.
[14] Schubart JR, Einbinder JS. Evaluation of a data warehouse in an academic
health sciences center. Int J Med Inform 2000;60:319–33.
[15] Rubin DL, Desser TS. A data warehouse for integrating radiologic and
pathologic data. J Am Coll Radiol 2008;5:210–7.
[16] Prokosch HU, Ganslandt T. Perspectives for medical informatics. Reusing the
electronic medical record for clinical research. Methods Inf Med
2009;48:38–44.
[17] Sarkar IN. Biomedical informatics and translational medicine. J Transl Med
2010;8:22.
[18] Gaze MN, Boterberg T, Dieckmann K, et al. Development of an electronic
database for quality assurance of radiotherapy in the International Society of
Paediatric Oncology (Europe) high risk neuroblastoma study. Radiother Oncol
2010;97:593–5.
[19] Fairchild A, Aird E, Fenton PA, et al. EORTC Radiation Oncology Group quality
assurance platform: establishment of a digital central review facility.
Radiother Oncol 2012;103:279–86.
[20] Bekelman JE, Deye JA, Vikram B, et al. Redesigning radiotherapy quality
assurance: opportunities to develop an efficient, evidence-based system to
support clinical trials – report of the national cancer institute work group on
radiotherapy quality assurance. Int J Radiat Oncol Biol Phys 2012;83:782–90.
[21] Nijsten SM, van Elmpt WJ, Mijnheer BJ, et al. Prediction of DVH parameter
changes due to setup errors for breast cancer treatment based on 2D portal
dosimetry. Med Phys 2009;36:83–94.
[22] Mathieu M. Good clinical practice: a question & answer reference
guide. Parexel International Corporation; 2009.
[23] Pieterse H. Richtsnoer voor Good Clinical Practice (CPMP/ICH/
95). Heerhugowaard: Profess Medical Consultancy B.V.; 2010.[24] Rao BR, Sandilya S, Niculescu R, Germond C, Goel A. Mining time-dependent
patient outcomes from hospital patient records. Proc AMIA Symp
2002;2002:632–6.
[25] Branson A, Hauer T, McClatchey R, Rogulin D, Shamdasani J. A data model for
integrating heterogeneous medical data in the Health-e-Child project. Stud
Health Technol Inform 2008;138:13–23.
[26] Wong K, Huang SH, O’Sullivan B, et al. Point-of-care outcome assessment in
the cancer clinic: audit of data quality. Radiother Oncol 2010;95:339–43.
[27] Ho KF, Farnell DJ, Routledge JA, et al. Comparison of patient-reported late
treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and
QLQ-H&N35) assessment after head and neck radiotherapy. Radiother Oncol
2010;97:270–5.
[28] Dekker A, Roelofs E, Meldolesi E, Valentini V, Lambin P. Ad-hoc data sharing
infrastructure for radiotherapy research collaboration: a tool for multicentric
clinical research. Radiother Oncol 2011;99:S155–6.
[29] Dekker A, Roelofs E, Meldolesi E, van Stiphout RGPM, Valentini V, Lambin P.
International data-sharing for radiotherapy research: an open-source based
infrastructure for multicentric clinical data mining. Radiother Oncol,
submitted for publication.
[30] Richesson RL, Krischer J. Data standards in clinical research: gaps, overlaps,
challenges and future directions. J Am Med Inform Assoc 2007;14:687–96.
[31] Deasy JO, Bentzen SM, Jackson A, et al. Improving normal tissue complication
probability models: the need to adopt a ‘‘data-pooling’’ culture. Int J Radiat
Oncol Biol Phys 2010;76:S151–4.
[32] Jayasurya K, Fung G, Yu S, et al. Comparison of Bayesian network and support
vector machine models for two-year survival prediction in lung cancer
patients treated with radiotherapy. Med Phys 2010;37:1401–7.
[33] Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume
combined with number of positive lymph node stations is a more important
prognostic factor than TNM stage for survival of non-small-cell lung cancer
patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys
2008;70:1039–44.
[34] Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external
validation of prognostic model for 2-year survival of non-small-cell lung
cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys
2009;74:355–62.
[35] Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P. The
importance of patient characteristics for the prediction of radiation-induced
lung toxicity. Radiother Oncol 2009;91:421–6.
[36] Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more
information from medical images using advanced feature analysis. Eur J
Cancer 2012;48:441–6.
[37] Vaidya M, Creach KM, Frye J, Dehdashti F, Bradley JD, El Naqa I. Combined PET/
CT image characteristics for radiotherapy tumor response in lung cancer.
Radiother Oncol 2012;102:239–45.
[38] Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment
planning and delivery. Radiother Oncol 2010;97:172–5.
